LoginSignup
Alector logo

Alector Stock

StockStock
ISIN: US0144421072
Ticker: ALEC
US0144421072
ALEC

Price

Frequently asked questions

What is Alector's market capitalization?

The market capitalization of Alector is $593.47M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Alector?

Alector's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.709. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Alector's stock?

Currently, 10 analysts cover Alector's stock, with a consensus target price of $13.75. Analyst ratings provide insights into the stock's expected performance.

What is Alector's revenue over the trailing twelve months?

Over the trailing twelve months, Alector reported a revenue of $61.51M.

What is the EBITDA for Alector?

Alector's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$177.40M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Alector?

Alector has a free cash flow of -$222.26M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Alector's stock?

The 5-year beta for Alector is 0.70. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Alector have, and what sector and industry does it belong to?

Alector employs approximately 241 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Alector's shares?

The free float of Alector is 88.12M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $593.47M

5Y beta

 0.70

EPS (TTM)

 -$1.709

Free Float

 88.12M

Revenue (TTM)

 $61.51M

EBITDA (TTM)

 -$177.40M

Free Cashflow (TTM)

 -$222.26M

Pricing

1D span
$5.436$6.345
52W span
$3.66$8.90

Analyst Ratings

The price target is $13.75 and the stock is covered by 10 analysts.

Buy

7

Hold

2

Sell

1

Information

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

241

Biotechnology & Drugs

Health Care

Identifier

ISIN

US0144421072

Primary Ticker

ALEC

Knockouts

Join the conversation
Sign upLogin